Europe Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others), By Type, By Country and Growth Forecast, 2021 - 2027

Europe Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others), By Type, By Country and Growth Forecast, 2021 - 2027

The Europe Immune Checkpoint Inhibitors Market would witness market growth of 16.4% CAGR during the forecast period (2021-2027).

The immunological checkpoint is situated on the surface of T cells or tumor cells and functions to prevent T cells from becoming overactive. Under normal conditions, inhibitory checkpoint protein prevents autoimmune disease damage, but when it encounters a tumor, it prevents T cells from contacting the tumor, decreasing the immune system's ability to recognize and destroy tumor cells. The immunological reaction of T cells can be considerably activated and the anti-tumor immune impact can be re-established by utilizing ICIs.

Immunosuppressive checkpoints have been used in a vast number of studies, and the number of effective immunological checkpoints available for immunotherapy is considerable, but more specific locations are still being explored. The efficacy of ICIs is linked to the expression of biomarkers such as PD-L1 expression, tumor mutation burden (TMB), and microsatellite instability (MSI).

In the WHO European Region, breast cancer is the most frequent malignancy in women, accounting for 28% of all cases. Breast cancer mortality increased across Europe from 1950 to the late 1980s, with the exception of Norway and Sweden. Breast cancer fatalities in the Region as a whole peaked in the 1990s, reaching 14.74 deaths over 100 000 population in 1994, before declining to 13.01 deaths per 100 000 in 2009.

The International Agency for Research on Cancer (IARC) released research in the "British Medical Journal" in 2010 that found discrepancies in breast cancer death rates across 30 European countries. Mortality declined by more than 20% in 15 countries between 1989 and 2006, but stayed stable or even climbed in central Europe. Iceland has seen a 45 percent decrease, whereas Romania has seen a 17 percent increase.

The Germany market dominated the Europe Immune Checkpoint Inhibitors Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $4,631.8 million by 2027. The UK market is estimated to witness a CAGR of 15.5% during (2021 - 2027). Additionally, The France market would experience a CAGR of 17.2% during (2021 - 2027).

Based on Application, the market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, and others. Based on Type, the market is segmented into PD-1 Inhibitor, PD-L1 Inhibitor, and CTLA-4 Inhibitor. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Beigene Ltd., Shanghai Junshi Biosciences Co., Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Merck Group (Merck Sharp & Dohme Corp.), Sanofi S.A., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.

Scope of the Study

Market Segments covered in the Report:

By Application

  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin lymphoma
  • Others
By Type
  • PD-1 Inhibitor
  • PD-L1 Inhibitor
  • CTLA-4 Inhibitor
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • AstraZeneca PLC
  • Beigene Ltd.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Bristol Myers Squibb Company
  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • Merck Group (Merck Sharp & Dohme Corp.)
  • Sanofi S.A.
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Immune Checkpoint Inhibitors Market, by Application
1.4.2 Europe Immune Checkpoint Inhibitors Market, by Type
1.4.3 Europe Immune Checkpoint Inhibitors Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May – 2021, Dec) Leading Players
Chapter 4. Europe Immune Checkpoint Inhibitors Market by Application
4.1 Europe Lung Cancer Market by Country
4.2 Europe Bladder Cancer Market by Country
4.3 Europe Melanoma Market by Country
4.4 Europe Hodgkin lymphoma Market by Country
4.5 Europe Other Application Market by Country
Chapter 5. Europe Immune Checkpoint Inhibitors Market by Type
5.1 Europe PD-1 Inhibitor Market by Country
5.2 Europe PD-L1 Inhibitor Market by Country
5.3 Europe CTLA-4 Inhibitor Market by Country
Chapter 6. Europe Immune Checkpoint Inhibitors Market by Country
6.1 Germany Immune Checkpoint Inhibitors Market
6.1.1 Germany Immune Checkpoint Inhibitors Market by Application
6.1.2 Germany Immune Checkpoint Inhibitors Market by Type
6.2 UK Immune Checkpoint Inhibitors Market
6.2.1 UK Immune Checkpoint Inhibitors Market by Application
6.2.2 UK Immune Checkpoint Inhibitors Market by Type
6.3 France Immune Checkpoint Inhibitors Market
6.3.1 France Immune Checkpoint Inhibitors Market by Application
6.3.2 France Immune Checkpoint Inhibitors Market by Type
6.4 Russia Immune Checkpoint Inhibitors Market
6.4.1 Russia Immune Checkpoint Inhibitors Market by Application
6.4.2 Russia Immune Checkpoint Inhibitors Market by Type
6.5 Spain Immune Checkpoint Inhibitors Market
6.5.1 Spain Immune Checkpoint Inhibitors Market by Application
6.5.2 Spain Immune Checkpoint Inhibitors Market by Type
6.6 Italy Immune Checkpoint Inhibitors Market
6.6.1 Italy Immune Checkpoint Inhibitors Market by Application
6.6.2 Italy Immune Checkpoint Inhibitors Market by Type
6.7 Rest of Europe Immune Checkpoint Inhibitors Market
6.7.1 Rest of Europe Immune Checkpoint Inhibitors Market by Application
6.7.2 Rest of Europe Immune Checkpoint Inhibitors Market by Type
Chapter 7. Company Profiles
7.1 AstraZeneca PLC
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Approvals and Trials:
7.2 Beigene Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 Shanghai Junshi Biosciences Co., Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.4 Bristol Myers Squibb Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Eli Lilly and Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Merck Group (Merck Sharp & Dohme Corp.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Sanofi S.A.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Approvals and Trials:
7.8.5.3 Acquisition and Mergers:
7.9 Merck & Co., Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. F. Hoffmann-La Roche Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Partnerships, Collaborations and Agreements:
7.10.5.2 Approvals and Trials:

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings